Skip to content

HeartSciences Inc.: 10-Q filed 2024-03-14

What HeartSciences Inc. reported in its quarterly report filed 2024-03-14 (fiscal Q3 2024): 45 published measures, 119 facts as tagged in accession 0000950170-24-031457.

This filing

Form
10-Q (quarterly report)
Filed
2024-03-14
Fiscal period
fiscal Q3 2024
Accession
0000950170-24-031457 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HeartSciences Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-01-3110,800,704USD
At 2023-04-303,287,233USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-01-312,166,868USD
At 2023-04-303,056,676USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-01-318,633,836USD
At 2023-10-31-1,649,682USD
At 2023-04-30230,557USD
At 2023-01-31-257,912USD
At 2022-10-311,082,676USD
At 2022-04-30-6,055,797USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-01-317,076,497USD
At 2023-04-301,660,467USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-11-01 to 2024-01-31-1,643,811USD92
2023-05-01 to 2024-01-31-4,759,044USD276
2022-11-01 to 2023-01-31-1,342,115USD92
2022-05-01 to 2023-01-31-4,721,929USD276

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-05-01 to 2024-01-31-4,533,809USD276
2022-05-01 to 2023-01-31-3,911,872USD276

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-05-01 to 2024-01-3115,656USD276
2022-05-01 to 2023-01-3110,716USD276

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-11-01 to 2024-01-3114,700USD92
2023-05-01 to 2024-01-3118,600USD276
2022-11-01 to 2023-01-311,950USD92
2022-05-01 to 2023-01-315,150USD276

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-05-01 to 2024-01-319,965,495USD276
2022-05-01 to 2023-01-314,935,280USD276

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-05-01 to 2024-01-31-15,656USD276
2022-05-01 to 2023-01-31-10,716USD276

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-01-31-65,516,242USD
At 2023-04-30-60,757,198USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-11-01 to 2024-01-3153,792,741shares92
2023-05-01 to 2024-01-3125,201,024shares276
2022-11-01 to 2023-01-318,240,798shares92
2022-05-01 to 2023-01-317,371,764shares276

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-11-01 to 2024-01-3153,792,741shares92
2023-05-01 to 2024-01-3125,201,024shares276
2022-11-01 to 2023-01-318,240,798shares92
2022-05-01 to 2023-01-317,371,764shares276

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-11-01 to 2024-01-31-0.03USD/shares92
2023-05-01 to 2024-01-31-0.19USD/shares276
2022-11-01 to 2023-01-31-0.16USD/shares92
2022-05-01 to 2023-01-31-0.64USD/shares276

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-11-01 to 2024-01-31-0.03USD/shares92
2023-05-01 to 2024-01-31-0.19USD/shares276
2022-11-01 to 2023-01-31-0.16USD/shares92
2022-05-01 to 2023-01-31-0.64USD/shares276

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-01-3158,393USD
At 2023-04-3061,428USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-05-01 to 2024-01-31326,578USD276
2022-05-01 to 2023-01-31149,153USD276

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-11-01 to 2024-01-31-1,525,382USD92
2023-05-01 to 2024-01-31-4,425,980USD276
2022-11-01 to 2023-01-31-1,309,303USD92
2022-05-01 to 2023-01-31-4,514,305USD276

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-01-318,690,750USD
At 2023-04-302,696,581USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-11-01 to 2024-01-31118,445USD92
2023-05-01 to 2024-01-31333,143USD276
2022-11-01 to 2023-01-3132,805USD92
2022-05-01 to 2023-01-31209,217USD276

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-01-311,706,009USD
At 2023-04-301,832,891USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-01-31415,076USD
At 2023-04-30631,369USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-01-311,568,818USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-01-3114,700USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-11-01 to 2024-01-311,535,521USD92
2023-05-01 to 2024-01-314,438,499USD276
2022-11-01 to 2023-01-311,310,493USD92
2022-05-01 to 2023-01-314,516,659USD276

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-01-31670,278USD
At 2023-04-30676,359USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-11-01 to 2024-01-3110,139USD92
2023-05-01 to 2024-01-3112,519USD276
2022-11-01 to 2023-01-311,190USD92
2022-05-01 to 2023-01-312,354USD276

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-11-01 to 2024-01-314,561USD92
2023-05-01 to 2024-01-316,081USD276
2022-11-01 to 2023-01-31760USD92
2022-05-01 to 2023-01-312,796USD276

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-11-01 to 2024-01-311,026,014USD92
2023-05-01 to 2024-01-312,606,057USD276
2022-11-01 to 2023-01-31667,235USD92
2022-05-01 to 2023-01-312,590,227USD276

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-11-01 to 2024-01-31509,507USD92
2023-05-01 to 2024-01-311,832,442USD276
2022-11-01 to 2023-01-31643,258USD92
2022-05-01 to 2023-01-311,926,432USD276

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-01-3163,611,630shares
At 2023-04-3010,118,440shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-01-317,076,497USD
At 2023-04-301,660,467USD
At 2023-01-311,930,952USD
At 2022-04-30918,260USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-01-3174,086,087USD
At 2023-04-3060,977,256USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-01-31482,743USD
At 2023-04-30529,224USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-01-31559,178USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-01-31548,951USD
At 2023-04-30533,295USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-01-31490,558USD
At 2023-04-30471,867USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-01-31584,427USD
At 2023-04-30623,391USD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-05-01 to 2024-01-3118,691USD276
2022-05-01 to 2023-01-3120,090USD276

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-11-01 to 2024-01-31-118,429USD92
2023-05-01 to 2024-01-31-333,064USD276
2022-11-01 to 2023-01-31-32,812USD92
2022-05-01 to 2023-01-31-207,624USD276

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2022-05-01 to 2023-01-315,194,740USD276

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2023-05-01 to 2024-01-3113,129USD276

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-05-01 to 2024-01-3114,700USD276
2022-05-01 to 2023-01-31-2,321USD276

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-05-01 to 2024-01-31-6,081USD276
2022-05-01 to 2023-01-312,770USD276

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-05-01 to 2024-01-31-216,293USD276
2022-05-01 to 2023-01-31427,142USD276

Inspect the source

Entity
HeartSciences Inc. / CIK 0001468492
Captured
2026-09-20T09:07:08.448Z
SEC response SHA-256
5eb1d09e2fca60365f9ba9d3f414c7100583b832746ccd0994084f9b163bc76c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001468492.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))